Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Pizotyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.79 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.79 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.79 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.79 |
| ▸ | DRD1 known ✓ | P21728 | 5/20 | 0.79 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.79 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.79 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.79 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 0.79 |
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.79 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.79 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.79 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.79 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.79 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.79 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.79 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.79 |
| ▸ | MTOR known ✓ | P42345 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pizotyline SCHEMBL1000902 | 1.00 | MAPK1 (1.00) | MAPK1MEN1MAPTKMT2AHRH1 | |
| Pizotyline SCHEMBL8771138 | 0.89 | DRD1 (1.00) | MAPK1MEN1MAPTKMT2AHRH1 | |
| Pizotyline SCHEMBL44122 | 0.89 | DRD1 (1.00) | MAPK1MEN1MAPTKMT2AHRH1 | |
| Pizotyline SCHEMBL29366884 | 0.89 | DRD1 (1.00) | MAPK1MEN1MAPTKMT2AHRH1 | |
| Pizotyline SCHEMBL11436430 | 0.88 | DRD1 (0.97) | MAPK1MEN1MAPTKMT2AHRH1 | |
| Pizotyline SCHEMBL365598 | 0.83 | CYP2D6 (1.00) | MAPK1MEN1MAPTKMT2AHRH1 | |
| Ketotifen SCHEMBL1170677 | 0.82 | DRD3 (1.00) | MAPK1MEN1MAPTKMT2AHRH1 | |
| Ketotifen SCHEMBL8810 | 0.82 | DRD3 (1.00) | MAPK1MEN1MAPTKMT2AHRH1 | |
| Ketotifen SCHEMBL226911 | 0.82 | DRD3 (1.00) | MAPK1MEN1MAPTKMT2AHRH1 | |
| Ketotifen SCHEMBL29400782 | 0.82 | DRD3 (1.00) | MAPK1MEN1MAPTKMT2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 647 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | UNIVERSITEIT GENT (BE) | 2021-06-15 | — | — | US | claimed |
| WO-2021078412-A1 | FRACTAL FORMULATIONS | MESSADEK JALLAL (BE) | 2021-04-29 | — | — | WO | claimed |
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | claimed |
| US-20190328768-A1 | MOLECULAR ADJUVANTS FOR ENHANCED CYTOSOLIC DELIVERY OF ACTIVE AGENTS | UNIVERSITEIT GENT (BE) | 2019-10-31 | — | — | US | claimed |
| US-20180296556-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2018-10-18 | — | — | US | claimed |
| US-20170172971-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-06-22 | — | — | US | claimed |
| US-20160220505-A1 | COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION | SOLUBEST LTD. (IL) | 2016-08-04 | — | — | US | claimed |
| US-9205047-B2 | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2015-12-08 | — | — | US | claimed |
| CN-103635179-A | Improved parenteral formulations of lipophilic pharmaceutical agents and methods of making and using the same | UNIV TEXAS | 2014-03-12 | — | — | CN | claimed |
| EP-2701684-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | Board Of Regents, The University Of Texas System (US) | 2014-03-05 | — | — | EP | claimed |
| US-20130059795-A1 | Novel Composition Of Matter For Delivering Lipid-Soluble Materials, And A Method For Producing It | LEAFPRO, LLC | 2013-03-07 | — | — | US | claimed |
| WO-2012148799-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-11-01 | — | — | WO | claimed |
| US-20120277249-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | GREENJAY THERAPEUTICS, INC. | 2012-11-01 | — | — | US | claimed |
| WO-2011109809-A2 | A NOVEL COMPOSITION OF MATTER FOR DELIVERING LIPID-SOLUBLE MATERIALS, AND A METHOD FOR PRODUCING IT | NEW AGRICULTURE, INC (US) | 2011-09-09 | — | — | WO | claimed |
| US-20100291191-A1 | TUNABLE SUSTAINED RELEASE OF A SPARINGLY SOLUBLE HYDROPHOBIC THERAPEUTIC AGENT FROM A HYDROGEL MATRIX | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2010-11-18 | — | — | US | claimed |
| US-20090098200-A1 | COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION | SOLUBEST LTD. (IL) | 2009-04-16 | — | — | US | claimed |
| US-20250381149-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2025-12-18 | — | — | US | disclosed |
| EP-0750495-A1 | DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS | R.P. Scherer Limited (GB) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995024893-A1 | DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS | R.P. SCHERER LIMITED (GB) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381149-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | NPC1L1, NPC1, ABCB4 | HRH1 2641/4885HTR2A 4186/4885HTR2C 4791/4885 |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | TLR9, PLA2G4C, STING1 | HRH1 2742/4885HTR2A 3727/4885HTR2C 4597/4885 |
| US-20190328768-A1 | MOLECULAR ADJUVANTS FOR ENHANCED CYTOSOLIC DELIVERY OF ACTIVE AGENTS | TLR9, PLA2G4C, STING1 | HRH1 2742/4885HTR2A 3727/4885HTR2C 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.